#None #Immuno-Oncology #TransCode #RNA

TransCode Therapeutics Bolsters Global Patent Portfolio

TransCode Therapeutics has recently taken significant strides in strengthening its intellectual property (IP) portfolio within crucial global markets by announcing major advancements in its patent applications. The latest developments center on RNA-based therapeutics aimed at fighting high-risk and advanced cancers, particularly leveraging immuno-oncology strategies. This article explores the implications of these patent approvals in Australia and Japan for the company's innovative cancer therapies.

Advancements in Australian and Japanese Patent Applications

On September 22, 2026, TransCode Therapeutics, Inc. (NASDAQ: RNAZ) unveiled that IP Australia has provided a Notice of Acceptance for its patent application numbered 2019349817, titled “Compositions and Methods for Immune Checkpoint Inhibition.” This specific application focuses on therapies utilizing nanoparticle compositions designed to deliver small interfering RNA (siRNA) molecules, which are crucial in the treatment of various cancers, including colon, lung, breast, pancreatic, and ovarian cancers.

Furthermore, in Japan, the Japan Patent Office (JPO) has issued a Notice of Allowance and subsequently granted Japanese Patent No. 7886877, corresponding to their application numbered 2023-540752 titled “Template Directed Immunomodulation for Cancer Therapy.” This patent outlines novel RNA-based immunomodulatory compositions, particularly focusing on innovative RNA oligonucleotides that selectively activate innate immune pathways within tumors.

Breakthrough Technologies for Cancer Treatment

The Australian patent highlights nanoparticle constructs that feature an iron oxide core and a dextran polymer coating, specifically designed to enhance the efficient delivery of targeted siRNA. Such compositions are intended to address several types of cancers, potentially revolutionizing the therapeutic landscape.

In parallel, the Japanese patent’s allowed claims are centered on compositions that specifically target cancers with expressed miR-21. This innovation utilizes advanced nanoparticle-based delivery mechanisms, further optimizing the approach for tumor targeting and cellular uptake.

Strategic Importance and Future Insights

The importance of these patent approvals cannot be overstated. Philippe P. Calais, Ph.D., the Chairman and CEO of TransCode Therapeutics, emphasized that these milestones reflect the ongoing commitment to expand and strengthen their IP in strategically significant territories globally. The success of these applications supports the company’s platforms for delivering RNA therapeutics and enriching its immuno-oncology capabilities, fulfilling unmet needs in cancer treatment.

Additionally, Co-founder and CSO Zdravka Medarova, Ph.D., addressed the broad spectrum of innovation behind their platforms, particularly the integration of precise RNA design with advanced delivery technologies. This forward-thinking approach aims not only to silence oncogenic drivers but also to activate innate immune pathways directly in cancer cells, cultivating an environment conducive to better patient outcomes.

The Australian patent application is projected to reach grant status, with an expected expiry date of September 6, 2039. Collectively, these advancements further bolster TransCode’s global IP estate, encompassing its leading RNA therapeutic candidates, including TTX-MC138.

Conclusion

TransCode Therapeutics' recent patent achievements highlight the company's commitment to pioneering RNA-based oncology treatments. By integrating sophisticated delivery mechanisms with potent RNA technologies, TransCode is poised to address the complexities of cancer treatment. As the journey continues in the realm of oncology, the innovative work being done at TransCode serves as a beacon of hope for patients facing the challenges of difficult-to-treat cancers.